Our Approach

Advancing REC-2282 Into Clinical Trials

We are currently developing REC-2282 for the treatment of Neurofibromatosis type-2 (NF2), a genetic disorder characterized by multiple recurrent tumors of the nervous system and is associated with significant morbidities and mortality. NF2 results from inactivating loss-of-function mutations in the tumor suppressor gene that encodes for neurofibromin-2, also known as schwannomin or merlin.


REC-2282 is a pan-histone deacetylase (HDAC) inhibitor that has been shown to also modulate the PI3K/pAKT/mTOR pathway - the signaling pathway activated due to loss of neurofribromin-2/merlin. By inhibiting AKT, REC-2282 can inhibit tumor growth by turning off signals needed for tumorigenesis.

In multiple non-clinical investigations, the molecule has demonstrated potent antitumor activity against multiple tumor types. Further, in Recursion's unbiased target-agnostic screening platform, REC-2282 demonstrated clear signals of efficacy in an in vitro model of NF2 and has physiochemical and other properties that support its potential in the treatment of NF2. In exploratory investigator-initiated studies, in a limited number of  patients with NF2 associated vestibular schwannomas and meningiomas, REC-2282 (previously AR-42) has demonstrated promising anti-tumor activity. Taken together, these data strongly support REC-2282’s further development in NF2.